Compare Ecopetrol SA (EC) vs Inovio Pharmaceuticals Inc (INO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ecopetrol SA vs Inovio Pharmaceuticals Inc — how do they compare? Ecopetrol SA trades at $17.17 (market cap $33.11B), while Inovio Pharmaceuticals Inc trades at $1.09 (market cap $112.19M). The key difference: Ecopetrol SA is far larger — about 295.1× Inovio Pharmaceuticals Inc's market cap, and Ecopetrol SA pays a 3.83% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Ecopetrol SA for 84 Days and Inovio Pharmaceuticals Inc for 43 Days on average.
| EC | INO | |
|---|---|---|
Market Cap | $33.11B | $112.19M |
Volume | 993,598 | 3,201,278 |
Sector | Energy | Health |
52-Week High | $18.26 | $2.65 |
52-Week Low | $8.61 | $0.66 |
Typical Hold Time | 84 Days | 43 Days |
Enterprise Value | $61.36B | $83.51M |
Dividend Yield | 3.83% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ecopetrol (EC) trades at $16.63, down 1.95% amid bearish technical signals and recent earnings misses. The stock shows attractive valuation metrics with P/E of 7.97 and P/S of 0.91, but faces declining revenue trends from $159.6B in 2022 to $119.7B in 2025. Recent management changes and board restructuring under Colombia's new government create uncertainty, while analyst sentiment remains cautious with 27% buy ratings.
The outlook remains challenged by declining profitability and political interference risks, though current valuations appear discounted. Investment opportunity exists if new management can stabilize operations, but investors face headwinds from earnings volatility and geopolitical factors in Colombia's state-controlled energy sector.
Inovio Pharmaceuticals trades at $1.155, up 2.21% today, with a bearish technical signal despite recent earnings beats. The company faces significant fundamental challenges with minimal revenue of $65,340 and substantial losses, reflected in a -130,000% net margin. Key catalyst is the October 30, 2026 FDA decision on INO-3107 for recurrent respiratory papillomatosis, with analyst consensus leaning bullish at a $2.75 price target.
Investment outlook hinges on FDA approval success; upside exists if INO-3107 gains approval, but persistent cash burn and lack of commercial revenue pose substantial risks. The stock remains speculative with high volatility expected around regulatory milestones.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Ecopetrol SA
Ecopetrol SA is a vertically integrated oil company with operations in Latin America and the United States Gulf Coast. Based out of Colombia, the company explores, develops, and conducts production activities in various countries. Ecopetrol works as the primary operator or partner in a joint venture, in a host of assets held onshore and offshore. Along with production, the company refines and markets crude oils and byproducts produced from its fields. Crude products are moved by Ecopetrol through a series of pipelines throughout Colombia, along with a network of third-party production centers and facilities.
Read more on EC →About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →
